Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab, Paclitaxel, and Carboplatin for Metastatic TNBC
NCT01009983Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2010
- Primary completion
- Jul 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in triple negative breast cancer (TNBC), sponsored by Wake Forest University Health Sciences. Started Mar 2010; status: terminated.
02
Drugs
panitumumab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01009983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01009983.